Old and new breakthroughs in neuromyelitis optica

Affiliations

¹ Department of Neurology, Medical Faculty, and Center of Neurology and Neuropsychiatry, LVR Klinikum, Heinrich-Heine-Universität, Düsseldorf D-40225, Germany. Electronic address: hans-peter.hartung@uni-duesseldorf.de.
² Department of Neurology, Medical Faculty, and Center of Neurology and Neuropsychiatry, LVR Klinikum, Heinrich-Heine-Universität, Düsseldorf D-40225, Germany.

Comment

Hans-Peter Hartung et al. Lancet Neurol. 2020 Apr.

. 2020 Apr;19(4):280-281.

doi: 10.1016/S1474-4422(20)30062-4. Epub 2020 Mar 18.

¹ Department of Neurology, Medical Faculty, and Center of Neurology and Neuropsychiatry, LVR Klinikum, Heinrich-Heine-Universität, Düsseldorf D-40225, Germany. Electronic address: hans-peter.hartung@uni-duesseldorf.de.
² Department of Neurology, Medical Faculty, and Center of Neurology and Neuropsychiatry, LVR Klinikum, Heinrich-Heine-Universität, Düsseldorf D-40225, Germany.

No abstract available

Comment on

Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, Fukaura H, Nomura K, Shimizu Y, Mori M, Nakashima I, Misu T, Umemura A, Yamamoto K, Sawada H. Tahara M, et al. Lancet Neurol. 2020 Apr;19(4):298-306. doi: 10.1016/S1474-4422(20)30066-1. Epub 2020 Mar 18. Lancet Neurol. 2020. PMID: 32199095 Clinical Trial.